Zealand seeks deals in obesity and beyond
With Boehringer locked in, the Danish biotech wants more partners for monotherapies, combos and more.
Spotlight – Vertex flexes its dealmaking muscle
The developer has two new collaborations in rare dystrophies, with Entrada and Tevard, but work is early and certain rivals are some way ahead.
Clinical and corporate developments over the Christmas period
A decent showing for Pfizer/Roche in haemophilia sets up a rivalry with Uniqure/CSL, and a smattering of deals get done before the year end – and before JP Morgan.
Ionis gets into gene editing
The company insists its $80m tie-up with Metagenomi will not lead to a loss of focus.
